CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia

• Published in: Heliyon
• Main Authors: Jie Liu, Mengyuan Xu, Xiaoqian Zhang, Zhuo Zhang, Tao Zhong, Hongjuan Yu, Yueyue Fu, Hongbin Meng, Jiawei Feng, Xindi Zou, Xueying Han, Liqing Kang, Lei Yu, Limin Li
• Format: Article
• Language: English
• Published: Elsevier 2024-07-01
• Subjects: B-cell acute lymphoblastic leukemia; Allogeneic hematopoietic stem cell transplantation, Chimeric antigen receptor-T; Refractory; Relapsed
• Online Access: http://www.sciencedirect.com/science/article/pii/S2405844024099687

Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy remain a subject of debate. In this research we investigated the efficiency and long-term outcomes of CD19 CAR-T bridging with allo-HSCT in R/R B-ALL patients. A total of 42 patients were brought into the cohort studies. Our findings revealed that patients who appected CAR-T followed by HSCT had a 1-year overall survival (OS) rate of 70 % and a 1-year leukemia-free survival (LFS) rate of 95 %. Moreover, patients who underwent this combined treatment had higher OS and LFS rates compared to those who received CAR-T therapy alone. In conclusion, the results of this clinical trial provide compelling evidence for the safety and efficacy of using CAR-T therapy as a bridging strategy to allo-HSCT in patients with R/R B-ALL.